Natera (NASDAQ:NTRA) Insider John Fesko Sells 781 Shares of Stock

Key Points

• Natera insider John Fesko sold 781 shares at an average price of $406, generating $317,086. The sale, conducted under a Rule 10b5-1 plan, covered tax obligations tied to vested equity awards and reduced his ownership by 0.40%.
• Natera shares traded at $436, near their 52-week high of $437.41, while the company’s latest quarterly revenue rose 37.7% year over year to $752.75 million and exceeded analyst estimates.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $394.31, although the company remains unprofitable and faces potential volatility ahead of its next earnings report.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 781 shares of the business's stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $406.00, for a total value of $317,086.00. Following the transaction, the insider directly owned 196,476 shares in the company, valued at $79,769,256. This trade represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $382,853.32.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The stock was sold at an average price of $321.53, for a total value of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05.

Natera Stock Performance

NASDAQ:NTRA traded up $11.58 during trading hours on Thursday, hitting $436.00. The company had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. The stock has a 50-day moving average price of $375.27 and a 200 day moving average price of $265.54. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same period in the prior year, the business earned ($0.74) EPS. The company's revenue for the quarter was up 37.7% on a year-over-year basis. As a group, research analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Natera during the second quarter valued at approximately $2,962,770,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company's stock worth $238,334,000 after purchasing an additional 11,793 shares in the last quarter. Maverick Capital Ltd. grew its stake in shares of Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company's stock worth $234,315,000 after buying an additional 227,605 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company's stock worth $226,220,000 after buying an additional 80,440 shares during the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Natera in the 2nd quarter worth approximately $199,960,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on Natera from $360.00 to $460.00 and gave the company an "overweight" rating in a research report on Wednesday, October 14th. BTIG Research upped their target price on Natera from $320.00 to $430.00 and gave the stock a "buy" rating in a report on Tuesday. Piper Sandler increased their target price on Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Finally, Royal Bank Of Canada raised their target price on Natera from $350.00 to $460.00 and gave the company an "outperform" rating in a research note on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.